KRAS Mutation
 
 

KRAS Mutation

Test name:
KRAS mutation

Order name:
KRAS

Specimen requirements:
Formalin-fixed paraffin embedded tissue (FFPE)

Minimum volume:
5-10 10µm sections of FFPE tissue in a sterile cup with stained H&E of same block.
If tumor percentage is less than 10% of total nuclei, macrodissection is required, send 5-10 10µm thickness unstained slides with stained H&E of same block.

Storage and Stability information:
Room temperature

Test performed:
Once per week

Methodology:
Real-time Polymerase Chain Reaction (PCR)

Reference range:
No KRAS mutation detected

Clinical significance:
Mutations in the K-RAS oncogene are frequently found in human cancers. The presence of these mutations has been shown to correlate with a lack of response to certain EGFR inhibitor therapies, such as cetuximab and panitumumab, in metastatic colorectal cancer patients. Screening for the K-RAS mutations aids doctors in selecting appropriate therapies for patients. This test detects the seven most common KRAS mutations: Gly12 Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val, and Gly13Asp.

CPT codes:
81275